Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MediniceWAR:ICE +8.24%25 PB Ratio is 8.28 as of Jul. 21, 2026, which is 172% above its 10-year median of 3.04. GuruFocus rates WAR:ICE with a GF Score™ of 25/100 and a GF Value™ of zł0.99 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 786 Medical Devices & Instruments companies, Medinice ranks worse than 89.19% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-21), Medinice's share price is zł77.50. Medinice's Book Value per Share for the quarter that ended in Mar. 2026 was zł9.36. Hence, Medinice's PB Ratio of today is 8.28.
The historical rank and industry rank for Medinice's PB Ratio or its related term are showing as below:
WAR:ICE'
s PB Ratio Range Over the Past 10 Years
Min: 0.67 Med: 3.04 Max: 15.4
Current: 8.28
During the past 10 years, Medinice's highest PB Ratio was 15.40. The lowest was 0.67. And the median was 3.04.
WAR:ICE's PB Ratio is ranked worse than 89.19% of 786
companies
in the Medical Devices & Instruments industry
Industry Median: 2.005
vs WAR:ICE: 8.28
During the past 12 months, Medinice's average Book Value Per Share Growth Rate was -10.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 17.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 21.70% per year.
During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of Medinice was 244.20% per year. The lowest was 17.30% per year. And the median was 46.70% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Medinice PB Ratio Related Terms
Medinice PB Ratio Historical Data
* Premium members only.
The historical data trend for Medinice's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Medinice's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medinice PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medinice's PB Ratio distribution charts can be found below:
* The bar in red indicates where Medinice's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Medinice's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Medinice (WAR:ICE) has a PB Ratio of 8.28 as of Jul. 21, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Medinice and its competitors. This is 172% above median its historical median of 3.04. Over the past decade, Medinice's PB Ratio has ranged from 0.67 to 15.40. According to the industry distribution chart, Medinice ranks #701 out of 786 companies in the Medical Devices & Instruments industry, placing it in the top 89.2%.
Is Medinice's PB Ratio too high?
Medinice's current PB Ratio of 8.28 is 172% above median its 10-year median of 3.04. Over the past 10 years, this metric has ranged from a low of 0.67 to a high of 15.40. The Medical Devices & Instruments industry median PB Ratio is 2.01. Medinice's value of 8.28 is 313% above this industry median. Based on the distribution chart, Medinice ranks #701 out of 786 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Medinice has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medinice's PB Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medinice ranks #701 out of 786 companies for PB Ratio. This places Medinice in the lower half of its industry. The industry median PB Ratio is 2.01. Medinice's value of 8.28 is 313% above this benchmark. Historically, Medinice's own PB Ratio has ranged from 0.67 to 15.40 over the past decade. While the company's 10-year median is 3.04 vs. the industry median of 2.01, Medinice has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.01, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medinice's current PB Ratio of 8.28 is 313% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Medinice and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medinice's current PB Ratio is 8.28, which is 172% above median its own 10-year median of 3.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medinice stock overvalued right now?
Based on GuruFocus' analysis, Medinice (WAR:ICE) is currently considered Significantly Overvalued. The stock's GF Value™ is zł0.99, compared to a current price of zł77.50 — trading 7728.3% above its estimated fair value. The current PB Ratio is 8.28, which is 172% above median its 10-year median of 3.04 and 313% above the Medical Devices & Instruments industry median of 2.01. Medinice's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Medinice (WAR:ICE), the current PB Ratio is 8.28 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medinice (WAR:ICE) Overvalued in 2026?
Based on GuruFocus' analysis, Medinice stock appears to be overvalued.
The current stock price of zł77.50 is trading 7728.3% above its estimated GF Value™ of zł0.99.
GuruFocus considers Medinice to be Significantly Overvalued.
Key valuation signals for WAR:ICE:
PB Ratio: 8.28 (172% above median its 10-year median of 3.04)
GF Value™: zł0.99 vs. price of zł77.50 (7728.3% above fair value)
Industry Position: 313% above the Medical Devices & Instruments median (#701 of 786)
No single metric tells the full story. See the WAR:ICE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medinice SA is a Polish company operating in the MedTech industry. The company is engaged in creating, developing and commercializing solutions in the field of medicine, in particular, cardiology and cardio surgery. Its portfolio includes close around 12 projects including CathAIO, an electrode with universal diagnostic, electrophysiological, haemodinamic and biohemic functions and can be used for RF ablation; cryoapplicator, for minimally invasive cardiosurgical cryoablation; Med-iConsole allows to reduce the need to use multiple computer devices during electrophysiological treatment; Minimax and Pacepress.
25GF Score
Get the complete analysis for WAR:ICE
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:ICE has been successfully added to your 
